Ketamine-based combination therapy

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameKetamine-based combination therapy
Drug Alias NameKetamine/Temsirolimus - Freedom BiosciencesFREE001FREE-001
ClassificationSmall molecules
Mechanisms of ActionGlutamate [NMDA] receptor antagonists
TargetsGlutamate [NMDA] receptor
Therapy Area/IndicationsDepressive Disorder, Treatment-Resistant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesFreedom Biosciences
China Registration ClassN/A

Develop Information

Active CompaniesFreedom Biosciences
Inactive CompaniesN/A
Active IndicationsDepressive Disorder, Treatment-Resistant
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A